- Global Blood Therapeutics ( NASDAQ: GBT ) a drug maker targeting the sickle cell disease (SCD) continues to trade higher in the pre-market Thursday with a gain of ~18% after Bloomberg reported that the company is drawing takeover interest.
- Some large pharma companies are eyeing a potential deal, the news agency said citing people familiar with the matter who chose to remain anonymous because the information is private.
- Global Blood ( GBT ) which markets SCD therapy Oxbryta is said to have engaged advisers to evaluate the takeover interest, the people said, adding that there is no certainty it will lead to a deal. A company representative declined to comment.
- Read: In a bullish thesis in JUne, Seeking Alpha contributor BioSci Capital Partners reiterated the Buy rating on the stock and reasoned why “Oxbryta is poised to enjoy a leaping growth rate.”
For further details see:
Global Blood Therapeutics up 18% after report on buyout interest